The European Academy of Neurology (EAN) annual congress included new research on neurofilament-light (NfL), an indicator of neuroaxonal damage and one of the more promising biomarkers in multiple sclerosis and other neurodegenerative conditions. Several recent publications have also presented interesting findings that suggest a role for NfL in MS diagnosis, prognosis and treatment selection. Read More
Latest News
Slide deck: COVID-19 – Epidemiology in Canada (July 7, 2020)
July 7, 2020Summary of epidemiology, testing and mortality rate; Canada and world statistics.
Update on B cells in MS pathophysiology
June 29, 2020SPECIAL REPORT
In the past few years, considerable attention has focussed on the role of B cells in the pathophysiology of multiple sclerosis, in large part because of the success of anti-CD20 monoclonal antibodies (e.g. rituximab, ocrelizumab) in reducing clinical and radiological disease activity. A novel agent, ofatumumab, is expected soon and other agents (e.g. ublituximab) are in development. Read More
Cognitive dysfunction in MS: Update from EAN
June 10, 2020The following is a summary of some of the key studies on cognitive dysfunction in multiple sclerosis presented at this year’s European Academy of Neurology virtual congress.